Great article:
Analyst Opinion
Currently two analysts rate BLRX as a BUY and have a $14.5/share average price target
Conclusions
December to remember is just ahead. BiolineRx will present four presentation/posters At 2021 ASH in mid December. Significant gains are possible going forward.
The company is discussing several partnership opportunities to move forward motixadortide in stem cell mobilization based on outstanding statistically significant Phase 3 GENESIS clinical trial results.
John DiPersio, MD, Washington University School of Medicine said this recently: “The results of the GENESIS study are extremely impressive, and all the more so when considering that almost 90% of the patients in the treatment arm proceeded to transplantation after only 1 apheresis session. This is a great achievement in alleviating the burden for the patients and reducing hospital resources. I believe these results make the combination of motixafortide and G-CSF a very attractive candidate for use in all patients with multiple myeloma undergoing autologous stem-cell transplantation.”
CEO Serlin November 18, 2021: "Taken together the positive results that we have seen in trial to date across both stem cell mobilization and pancreatic cancer, reflect the underlying versatility of Motixafortide as the potential backbone of improved treatments for both hematological and solid tumor cancers. We have an opportunity to highlight this fact that this year's American Society of Hematology Annual Meeting & Exposition or ASH, which is taking place December 11th to December 14."
During the November 18, 2021 3Q financial and corporate update the company reported that it held $62.2M of cash, cash equivalents in short-term bank deposits as of September 30th, 2021. CFO Mali Zeevi We commented "We believe we are well-financed to achieve multiple potentially value creating milestones."
The discussion in this article hopefully highlights that the potential therapeutic benefits of motixafortide can be extended to a myriad of types of liquid and solid cancers because of its strong ability to block CXCL12's interaction and binding onto chemokine receptor CXCR4. In short, the therapeutic possibilities with motixafortide seem to be endless and I believe that in the future with more resources and through partnerships it will be investigated in more indications with high unmet needs.
Regarding cancer tumor vaccine candidate AGI-134 CEO Serlin updated on 3Q 2021 conference call last week: "In September, 2019, we announced positive safety data. And later that same month, we moved quickly to initiate Part 2 to dose expansion phase. As we have discussed, the COVID-19 pandemic did impact enrollment for a period of time, but it's now resumed. At this stage, it looks like we will complete recruitment by the end of this year and be in a position to announce results from the trial in the first half of next year. "
Currently two analysts rate BLRX as a BUY and have a $14.5/share average price target. Prolific Seekingalpha contributor believes that BiolineRx will be acquired in 2020 in the high-teens price area.
I recommend that those interested in BLRX shares do a detailed review of the risks an uncertainties related to investing in this company as detailed in the company's filings with the SEC.
Disclosure: I/we have a beneficial long position in the shares of BLRX either through stock ownership, options, or other derivatives.
